Published in Law and Health Weekly, January 20th, 2007
The findings were presented at the 4th Annual Commercialisation of Tissue Engineering & Cell Therapy meeting in London, U.K.
The data presented by David Eisenbud, MD, executive VP and chief medical officer for ABH, compared in vitro potency, as well as in vivo efficacy at 3, 6 and 9 month intervals. Results demonstrated that Celaderm stored at -70 degrees Celsius and -20 degrees Celsius maintained product viability at both temperatures while being highly effective in treating wounds when...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.